Dr. Brian R. Zeno, M.D.
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- Northeastern Ohio University College of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 252
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Northeastern Ohio University College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
OH license 35.087832 -
Critical Care Medicine (Internal Medicine) Physician
OH license 35.087832 -
Specialist
OH license 87832
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Riverside Methodist Hospital Columbus, OH
- Grant Medical Center Columbus, OH
Medical groups
- Ohiohealth Corporation (2,314 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 252
- Services billed
- 718
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 258 | 107 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 100 | 97 |
| Critical care, first 30-74 minutes | 98 | 57 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 68 | 25 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 65 | 65 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | 33 | 33 |
| Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes | 27 | 27 |
| Ultrasonic guidance for blood vessel access | 20 | 19 |
| Emergent insertion of breathing tube into windpipe using an endoscope | 18 | 18 |
| Insertion of non-tunneled central venous tube for infusion (5 years or older) | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $1,500 in total to this clinician.
| Intuitive Surgical, Inc. | $1,500 |
|---|
| Education | $1,500 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Intuitive Surgical, Inc. Feb 11, 2025 | Education Da Vinci Surgical System · SURGERY · in-kind | $1,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $109,746 in research payments for these studies, mostly to the institutions running them.
- A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - A phase 3, 52-week, randomized, double-blind, placebo-controlled, para
GlaxoSmithKline, LLC. - A multi-center, randomized, double-blind, parallel-group, placebo-cont
GlaxoSmithKline, LLC. - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler MDI Rel…
AstraZeneca Pharmaceuticals LP - A Randomized Double-Blind Parallel Group Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participan…
AstraZeneca Pharmaceuticals LP - A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.